TY - JOUR
T1 - Gene-expression profiles in hereditary breast cancer
AU - Hedenfalk, Ingrid
AU - Duggan, David
AU - Chen, Yidong
AU - Radmacher, Michael
AU - Bittner, Michael
AU - Simon, Richard
AU - Meltzer, Paul
AU - Gusterson, Barry
AU - Esteller, Manel
AU - Raffeld, Mark
AU - Yakhini, Zohar
AU - Ben-Dor, Amir
AU - Dougherty, Edward
AU - Kononen, Juha
AU - Bubendorf, Lukas
AU - Fehrle, Wilfrid
AU - Pittaluga, Stefania
AU - Gruvberger, Sofia
AU - Loman, Niklas
AU - Johannsson, Oskar
AU - Olsson, Håkan
AU - Wilfond, Benjamin
AU - Sauter, Guido
AU - Kallioniemi, Olli P.
AU - Borg, Ake
AU - Trent, Jeffrey
PY - 2001/2/22
Y1 - 2001/2/22
N2 - Background Many cases of hereditary breast cancer are due to mutations in either the BRCA1 or the BRCA2 gene. The histopathological changes in these cancers are often characteristic of the mutant gene. We hypothesized that the genes expressed by these two types of tumors are also distinctive, perhaps allowing us to identify cases of hereditary breast cancer on the basis of gene-expression profiles. Methods RNA from samples of primary tumors from seven carriers of the BRCA1 mutation, seven carriers of the BRCA2 mutation, and seven patients with sporadic cases of breast cancer was compared with a microarray of 6512 complementary DNA clones of 5361 genes. Statistical analyses were used to identify a set of genes that could distinguish the BRCA1 genotype from the BRCA2 genotype. Results Permutation analysis of multivariate classification functions established that the gene-expression profiles of tumors with BRCA1 mutations, tumors with BRCA2 mutations, and sporadic tumors differed significantly from each other. An analysis of variance between the levels of gene expression and the genotype of the samples identified 176 genes that were differentially expressed in tumors with BRCA1 mutations and tumors with BRCA2 mutations. Given the known properties of some of the genes in this panel, our findings indicate that there are functional differences between breast tumors with BRCA1 mutations and those with BRCA2 mutations. Conclusions Significantly different groups of genes are expressed by breast cancers with BRCA1 mutations and breast cancers with BRCA2 mutations. Our results suggest that a heritable mutation influences the gene-expression profile of the cancer.
AB - Background Many cases of hereditary breast cancer are due to mutations in either the BRCA1 or the BRCA2 gene. The histopathological changes in these cancers are often characteristic of the mutant gene. We hypothesized that the genes expressed by these two types of tumors are also distinctive, perhaps allowing us to identify cases of hereditary breast cancer on the basis of gene-expression profiles. Methods RNA from samples of primary tumors from seven carriers of the BRCA1 mutation, seven carriers of the BRCA2 mutation, and seven patients with sporadic cases of breast cancer was compared with a microarray of 6512 complementary DNA clones of 5361 genes. Statistical analyses were used to identify a set of genes that could distinguish the BRCA1 genotype from the BRCA2 genotype. Results Permutation analysis of multivariate classification functions established that the gene-expression profiles of tumors with BRCA1 mutations, tumors with BRCA2 mutations, and sporadic tumors differed significantly from each other. An analysis of variance between the levels of gene expression and the genotype of the samples identified 176 genes that were differentially expressed in tumors with BRCA1 mutations and tumors with BRCA2 mutations. Given the known properties of some of the genes in this panel, our findings indicate that there are functional differences between breast tumors with BRCA1 mutations and those with BRCA2 mutations. Conclusions Significantly different groups of genes are expressed by breast cancers with BRCA1 mutations and breast cancers with BRCA2 mutations. Our results suggest that a heritable mutation influences the gene-expression profile of the cancer.
UR - http://www.scopus.com/inward/record.url?scp=0035931947&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035931947&partnerID=8YFLogxK
U2 - 10.1056/NEJM200102223440801
DO - 10.1056/NEJM200102223440801
M3 - Article
C2 - 11207349
AN - SCOPUS:0035931947
SN - 0028-4793
VL - 344
SP - 539
EP - 548
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 8
ER -